SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (998)7/17/1997 3:40:00 PM
From: Peter Church   of 6136
 
Merck may be self-interested, but they have a point. There isn't that much data to base conclusions on, only indications. Merck is taking a conservative position. Agouron has a small data set and is extrapolating. The question, "Is Nelfinovir different?" in terms of cross resistance, may not be answered for another year (in Geneva). In the meantime, doctors and patients will be left to make decisions based on marketing preferences, PR, and willingness to risk a new therapy. It would be nice to get an early resolution of the question, but it may not be possible for a year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News